A promising molecular target for liver cancer therapy

	Tweet

Although GABA and GABA receptors function as an inhibitory neurotransmitter in the mature CNS, abnormal levels of gene and protein expression of some GABA receptor subunits have been detected in many malignant tumors, such as π subunit in pancreatic cancer. This indicates that GABAergic system may play an important role in the pathogenesis and development of malignant tumors, and their expression levels are important for prognosis.

A research to be published in the World Journal of Gastroenterology on December 21,2008 addresses a new finding about this hotpoint. The research team led by Prof. Li from Cancer Institute of Central South University used in silico databases to identify genes that were overexpressed in HCC.

In this way, they identified the overexpression of GABA receptor α3 subunit (GABRA3) in HCC cells. Knockdown of endogenous GABRA3 expression in HepG2 attenuated HCC cell growth, suggesting its role in HCC cell viability. 

They also determined the in vitro and in vivo effect of GABA on the proliferation of GABRA3-positive cell lines, and found that GABA increased HCC growth in a dose-dependent manner.

Notably, the addition of GABA into the cell culture medium promoted the proliferation of GABRA3-expressing HepG2 cells, but not GABRA3-knockdown HepG2 cells. That means GABA stimulates HepG2 cell growth through GABRA3.

These findings highlight the importance of elucidating the role GABAergic activity play in the pathogenesis of HCC. GABA and GABRA3 could play important roles in HCC development and progression and can be a promising molecular target for the development of new diagnostic and therapeutic strategies for HCC.

###

Reference - - Liu Y, Li YH, Guo FJ, Wang JJ, Sun RL, Hu JY, Li GC. Gamma-aminobutyric acid promotes human hepatocellular carcinoma growth through overexpressed gamma-aminobutyric acid A receptor ?3 subunit. World J Gastroenterol 2008;14(47) - - 7175-7182

Contact - - Lin Tian

86-105-908-0039
World Journal of Gastroenterology

Correspondence to - - Guan-Cheng Li, MD, PhD, Tumor Immunobiology Laboratory of Cancer Research Institute, Central South University, Changsha 410078, Hunan Province, China.

Telephone - - +86-731-4805445
Fax - - +86-731-2355042

RELATED STORIES:
Eating mandarins reduces the risk of liver disease, hardened arteries and insulin resistance   Experts find rogue stem cells in liver cancer   Saffron shows promise in preventing liver cancer   More evidence coffee may cut risk of liver cancer   The ignored virus that causes liver cancer   Mayo Clinic Studies Identify Risk Factors in Rising Trend of Liver Cancer   How to differentiate benign from malignant bile duct strictures?   New Technique in Treating Patients With Liver Cancer Proves Effective   The relationship between body mass index and age at hepatocellular carcinoma onset   Omega-3 fatty acids inhibit the growth of liver cancer cells   Sex hormone explains men’s higher liver cancer risk   A diagnostic marker in hepatocellular carcinoma   Liver cancer in cirrhotic patients effectively treated with radiofrequency ablation   Liver Tumors Associated with Metabolic Syndrome Differ from Other Tumors   Studies of patients with cirrhosis uncover limitations in liver cancer screening   Cycles of Cell Death, Proliferation Key to Liver Cancer   Combination Therapy Improves Survival Time For Patients With Advanced Liver Cancer   Researchers Find That Targeted Therapy Combination Overcomes Treatment Resistance in Liver Cancer   Liver cancer is likely caused by cycles of liver cell death and renewal   Researchers Identify Gene Linked to Aggressive Progression of Liver Cancer   Blacks with Liver Cancer More Likely to Die   Statins may cut liver cancer risk in diabetics

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]